Avacta Group (LON:AVCT) Stock Price Passes Below 200-Day Moving Average - Time to Sell?

Key Points

• Technical signal: Avacta crossed below its 200‑day moving average (GBX 65.35), trading as low as GBX 64 and last at GBX 66.20 on volume 5,272,169 shares.
• Fundamental risk: The company is unprofitable (P/E -3.91) with a market cap of £311.33M and an extremely high debt‑to‑equity ratio (14,168.75), while liquidity metrics are mixed (quick ratio 4.96 vs current ratio 0.79).

Avacta Group Plc (LON:AVCT - ) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 65.35 and traded as low as GBX 64. Avacta Group shares last traded at GBX 66.20, with a volume of 5,272,169 shares.

Avacta Group Stock Up 3.7%

The firm has a 50 day simple moving average of GBX 62.99 and a two-hundred day simple moving average of GBX 65.35. The company has a quick ratio of 4.96, a current ratio of 0.79 and a debt-to-equity ratio of 14,168.75. The stock has a market capitalization of £311.33 million, a P/E ratio of -3.91 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.